The subcellular localisation of doxorubicin and Victoria Blue BO (VBBO) in a murine mammary tumour cell line EMT6-S, and the resistant sub-line EMT6-R was studied, using confocal microscopy, in order to investigate their sites of action. In cells treated with doxorubicin (10 mM) for 90 min, the pattern of intracellular drug distribution differed between the two cell lines. Doxorubicin was found to localise mainly in the nucleus of the sensitive cell line, whereas weak fluorescence was observed in the cytoplasm of the resistant cells, in a punctuate pattern, with no nuclear involvement. The drug also appeared to be effluxed more rapidly by the resistant cell line. The accumulation of doxorubicin at various time intervals over 1 h in EMT6-S cells showed that the drug clearly interacted with both the plasma membrane and the nucleus. In contrast to doxorubicin, the intracellular distribution of VBBO in both EMT6-S and EMT6-R was similar, VBBO was clearly localised throughout the cytoplasm, in a punctuate pattern, which may be consistent with the widespread distribution of mitochondria. A more apical pattern of accumulation was noted in the EMT6-R cell line. No interaction with the plasma membrane was evident. These results indicate that the main modes of action for the two drugs differ markedly, suggesting involvement of both the membrane and the nucleus in the case of doxorubicin, but mitochondrial involvement for VBBO.
Introduction
express P-glycoprotein (Pgp), a 170-180 kDa glycoprotein which acts as an energy-dependent efMultiple drug resistance (MDR) is a major problem in flux pump, in their cell membrane. Pgp has also been cancer chemotherapy. In many cases the initial refound in the Golgi apparatus ) sponse to treatment is encouraging, with tumour and the nucleus (Baldini et al. 1995) of MDR cells. shrinkage due to the elimination of drug-sensitive
Other studies suggest that Pgp may act as an intracelcells, however, when relapse occurs, it is often associlular pH regulator, possibly sequestering drugs into ated with the development of drug resistance. There specific subcellular compartments which may mediate remains a constant challenge to identify novel antiefflux or affect their pH-dependent binding to cellular cancer agents to try to overcome the problem of targets (Thiebault et al. 1990; Roepe 1992) . MDR. Acquired resistance occurs after exposure to MDR appears to be multifactorial, with many difchemotherapeutic agents, and is often associated with ferent mechanisms contributing to the MDR phenoa decreased intracellular concentration of the drug.
type. One important phenomenon associated with Tumour cells displaying the 'classic' MDR phenotype MDR is an altered subcellular drug distribution are resistant to anthracyclines, Vinca alkaloids, epi- . Various fluorescence studies dophyllotoxins, taxol and actinomycin D (Gottesman have demonstrated that the development of MDR is and Pastan 1993), and have been found to over associated with a relative shift of doxorubicin or daunorubicin fluorescence from the nucleus to the as the triarylmethane dye Victoria Blue BO (VBBO). cytoplasm (Schuurhuis et al. 1989; Studies comparing the cytotoxicity of VBBO with 1990; Gervasoni et al. 1991; .
that of the more conventional anti-cancer drug, doxoSchuurhuis et al. (1991) suggest that this phenomenon rubicin, in a murine mammary tumour cell line may make an important contribution to the resistance EMT6-S, and the resistant sub-line EMT6-R, have displayed against anthracyclines by MDR cells.
shown the MDR cell line to be considerably more The intracellular distribution of the anthracycline, susceptible to VBBO than to doxorubicin (Waindoxorubicin, is of interest due to its widespread use in wright et al. 1999 ). In addition, pre-treatment of the treatment of cancer and to extensive studies into EMT6 cells with VBBO, prior to exposure to doxoruits mode of action (Carter 1975; Tewey et al. 1984;  bicin, increased doxorubicin toxicity in both cell lines Tritton 1991; Gewirtz 1999). The mechanisms by two-fold, suggesting that VBBO is independent of the which doxorubicin exerts its cytotoxicity have proved Pgp efflux pump. This was confirmed by the addition to be very complex and several theories have been of verapamil, which increased the cytotoxicity of proposed. It is known to act mainly by intercalation doxorubicin against EMT6-R cells 18-fold, and with DNA and interaction with nucleic acids and against EMT6-S cells 2-fold, but had no effect on the nuclear components, such as DNA topoisomerase II cytotoxic effect of VBBO against these cell lines ( Gabbay et al. 1976; Tritton 1991; Gewirtz 1999) . In (Burrow et al. 2000) . addition, doxorubicin has been shown to be cytotoxic
The aim of this study was to use confocal microwithout entering the cell and this cytotoxicity does not scopy to examine the intracellular localisation of necessarily correlate with DNA damage or inhibition doxorubicin and VBBO in EMT6 cells, and to comof DNA synthesis (Tritton and Yee 1982 (Zeisel 1993) . Tritton (1991) mental with 10% (v / v) foetal calf serum, 200 mM postulates that doxorubicin exerts its cytotoxicity by L-glutamine (Sigma, Poole, UK), and penicillin / 4 21 interacting with, and damaging the functions of, both streptomycin solution at 1310 units ml and 10 mg 21 the plasma membrane and nuclear DNA, and that for ml , respectively, in 0.9% (w / v) Sigma). A sterile cytotoxicity to occur, the activation of the protein quartz coverslip (suprasil, 0.5 mm diameter 3 0.2 mm kinase C (PKC) pathway, following membrane perthick, Heraeus Silica & Metals Ltd., Byfleet, UK) was turbation, is crucial for signal transduction between placed into each petri dish and the cells were allowed the cell surface and the nucleus.
to attach for 3 days (EMT6-S cells) or 4 days (EMT6-Doxorubicin has been shown to interact with other R cells) whilst incubating at 37 8C, 5% CO : 95% air. of an attached syringe and the cells were examined for 1991; Coley et al. 1993) , autofluorescence. further adding to the complexity of the drug's action.
The incubating medium was aspirated from the A novel area of study involves the use of photopetri dishes, replaced with medium containing doxodynamic therapy employing agents based on commerrubicin (10 mM), and the cells were incubated for 90 cial cationic dyes with photodynamic potential, such min, under conditions described above. The cells were rinsed with RPMI 1640 medium, incubated for a with the widespread distribution of mitochondria. further 40 min and examined with a scanning laser Some diffuse fluorescence was evident in the nuclear confocal fluorescence microscope (objective lens region after 8 min( Figure 3b) ; however, this did not Zeiss 403 Ultafluar, numerical aperture (N.A.) 0.7) appear to increase over time. (Figures 3b -3g ). Interfitted with an argon ion laser at 488 nm 1 assay estingly, there was no evidence of interaction with the maximum projection. plasma membrane. Uptake of VBBO by the resistant cells appeared to Time course studies be slower than in the sensitive cells (Figures 4a -4g) ) with an increase in accumulation of the drug seen over EMT6-S and EMT6-R cells were grown as described 40 min (Figures 4a -4f ). This concentration did not above. The incubating medium was aspirated from the appear to change between 40 and 60 min(Figures 4f & petri dishes, replaced with medium containing VBBO 4g). VBBO was again seen to be localised throughout at a concentration of 5 mM, and images were taken at the cytoplasm, however, there did appear to be an various intervals over the period of 1 h using a apical accumulation of the drug in these cells, which scanning laser confocal fluorescence microscope (obmay indicate localisation within the Golgi apparatus jective lens Zeiss 403 Ultafluar, numerical aperture or mitochondria. Weak, diffuse fluorescence appeared (N.A.) 0.7) fitted with a helium neon laser at 633 nm.
in the nuclear region after 8 min (Figure 4b ) increasThis procedure was repeated for EMT6-S cells using ing somewhat over 25 min (Figures 4b -4e ). Howdoxorubicin at a concentration of 10 mM, and using ever, the main area of localisation was the cytoplasm. an argon ion laser at 488 nm for the confocal microIn common with EMT6-S cells no interaction with the scopy.
plasma membrane was seen. Doxorubicin was also taken up rapidly by EMT6-S cells and could be seen in the plasma membrane and Results nucleus after only 2 min (Figure 5a ). Localisation in the plasma membrane and nucleus increased with Intracellular localisation of doxorubicin in treated time up to 10 min (Figures 5a -5d) , however, very
EMT6-S and EMT6-R cells, following recovery in
little drug was seen in the cytoplasm. There also drug-free medium appeared to be apical concentration of doxorubicin in Nuclear localisation of doxorubicin in the EMT6-S the plasma membrane of the cell (Figures 5a -5g (Figures 1a -1f ) and some the plasma membrane, but subsequent images show cytoplasmic distribution was also seen (Figures 1b -this concentration to diminish (Figures 5e -5h) . The 1e). No evidence of localisation in the plasma memnuclear accumulation appeared to be slightly reduced brane was noted. In EMT6-R cells weak fluorescence after 15 min (Figure 5e ), and continued to diminish was seen in the cytoplasm, in a punctuate pattern over 40 min (Figure 5h ). (Figures 2a -2f ) but no nuclear accumulation was noted. The intensity was increased 3 10 to image the EMT6-R cells compared to that used with EMT6-S Discussion cells.
A clear difference was seen in intracellular doxorubiTime course studies cin accumulation between EMT6-S and EMT6-R cells. Doxorubicin was shown to localise predomiLocalisation of VBBO in EMT6-S cells was markedly nantly in the nucleus of the parental cell line, whereas different to that of doxorubicin. The drug was taken weak fluorescence was observed in the cytoplasm of up rapidly by the cells and could clearly be seen after the EMT6-R cells, in a punctuate pattern, but no 4 min (Figure 3a) . The concentration of drug in the nuclear accumulation was observed. Meschini et al. cell increased marginally over the next 11 min (Fig-(1994) also found a lack of nuclear accumulation in ures 3b -3c) and remained constant until 60 min the resistant strain of the human breast cancer cell when a slight decrease was noted (Figures 3d -3g) .
line, MCF-7 DX; however, in contrast to our studies VBBO was clearly localised throughout the cytothese authors showed extensive cytoplasmic localisaplasm in a punctuate pattern, which may be consistent tion. Other studies have also found distinct differ- Duffy et al. 1996; Davies et al. 1996) . distribution of doxorubicin in MCF-7 DX (resistant) single scan with the laser beam. * Scale of fluorescence intensity (gray -255, maximum; black -0, minimum) cells. The intracellular concentration of the drug was ised in the nuclei of the parental cell lines, with only increased and it appeared to Iocalise in a specific area weak cytoplasmic fluorescence seen in some cells. close to the nucleus. This supports a recent study by This is in good agreement with the findings of the Rutherford and Willingham (1993) who identified the present study. Meschini et al. (1994) also examined accumulation of anthracycline molecules in the transcells which had previously been exposed to doxorubiGolgi system of resistant cells which were also treated cin but were then allowed to recover for 71 h in a with verapamil.
drug-free medium. Complete efflux of doxorubicin Several workers have shown that MDR can be from the nucleus was shown, with occasional fluoresassociated with altered intracellular drug accumulacent vesicular structures localised to perinuclear retion and Iocalisation (Fojo et al. 1985; gions in the cytoplasm. Other workers (Peterson and al. 1986; Coley et al. 1993) . ) Truet 1978 Hindenburg et al. 1987; Vale 1987) have have suggested that, in addition to drug efflux, Pgp suggested that doxorubicin diffuses across the memmay be involved in the relocalisation of drugs by brane and binds to anionic vesicles which are transpumping them into other cellular organelles away ported back to the cell surface via microtubules. from their cytotoxic targets. Other studies suggest that Meschini et al. (1994) support this hypothesis, and a pH shift in some cytoplasmic organelles may consuggest that the accumulation of doxorubicin in the tribute to the redistribution of anticancer drugs in perinuclear region may indicate binding to pre-lyso-MDR cells (Thiebault et al. 1990; Schindler et al. somes and the Golgi apparatus since these organelles 1996) . Anthracyclines accumulate in their protonated are associated with the transport of secretory vesicles form on the side of the membrane at which the pH is to the cell surface. Doxorubicin is also known to lower, due to their basic character, suggesting that localise in mitochondria and to exert some cytotoxicicationic molecules become trapped in acidic cytoty via damage to the electron transfer chain in mitoplasmic vesicles (Millot et al. 1997) .
chondria (Goormatigh and Russchaert 1984; Ellis et Doxorubicin was rapidly taken up by EMT6-S al. 1987 ). cells, with the drug clearly localising in the plasma
The intracellular distribution of VBBO was found membrane and nucleus after only 2 mm. The drug to be markedly different to that of doxorubicin.VBBO continued to accumulate in the plasma membrane and was taken up extremely rapidly, with intense fluoresnucleus for up to 10 min; however, very little fluorescence evident after only 4 min, increasing only margicence was noted in the cytoplasm. This supports the nally up to 15 min. The concentration of the drug mechanism of action suggested by Tritton (1991) who appeared to be constant up to 60 min when a slight proposed that perturbation of the membrane induces decrease was noted. VBBO was clearly distributed subsequent signal transduction via diacylglycerol and widely throughout the cytoplasm, in a punctuate protein kinase C. In these studies Tritton was able to pattern, which may be consistent with the distribution emphasise a cytotoxic, nuclear response which did not of mitochondria.Very little evidence of nuclear localiinvolve drug -nucleus interaction by binding to sation was seen. In contrast to doxorubicin, no interpolymers to prevent uptake. There also appeared to be action between VBBO and the plasma membrane was apical concentration of doxorubicin in the plasma demonstrated. The resistant cell line initially appeared membrane of the sensitive cells. Considerable acto show slower uptake of VBBO than the parental cumulation of doxorubicin in the plasma membrane line, with a more gradual increase in cellular accumuwas evident up to 10 min, although after this time the lation. Equilibration was seen at 40 min, compared to localisation changed. The nuclear accumulation did 15 min in EMT6-S cells. Although similar distribunot appear to increase, therefore it must be assumed tion of the drug was seen throughout the cytoplasm in that the doxorubicin diffused out of the cell into the each cell line, there appeared to be an apical consurrounding medium. Less nuclear accumulation was centration of doxorubicin in the resistant line. Very seen after 15 min and very little fluorescence was little nuclear association was observed and there was noted in the plasma membrane or cytoplasm.
no apparent interaction with the plasma membrane. Meschini et al. (1994) 
